Multi‐cohort evaluation of plasma p ‐tau217+ classification accuracies and thresholds for early detection of amyloid‐beta pathology

Abstract

Background: Blood biomarkers represent the next generation of Alzheimer's disease (AD) diagnostics, enabling noninvasive, inexpensive, and scalable monitoring of amyloid‐beta (Aβ) plaque (A) and tau neurofibrillary tangles (T) pathologies and neurodegeneration (N).